Document:

ex10-5.htm

Exhibit 10.5

 

TERMINATION OF EXECUTIVE EMPLOYMENT AGREEMENT

 

This Termination of Executive Employment Agreement (this "Agreement") between Cocrystal Pharma, Inc., a Delaware corporation (f/k/a Biozone Pharmaceuticals, Inc.) (including its successors and assigns, the "Company"), and Dr. Gary Wilcox (the "Executive") is dated as of February 23, 2015. This Agreement terminates the Executive Employment Agreement dated as of January 2, 2014 by and between the Company and Executive (the "Employment Agreement"). Capitalized terms used but not defined herein shall have the meanings given to such terms in the Employment Agreement. All references to Sections herein shall be references to such Sections in the Employment Agreement unless otherwise noted.

 

RECITALS

 

WHEREAS, the parties hereto desire to terminate the Employment Agreement; and

 

WHEREAS, the Executive will continue providing services to the Company as an employee and as its Chief Executive Officer.

 

NOW THEREFORE, in consideration of the foregoing, of the mutual promises contained herein and of other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:

 

1.        Termination of Employment Agreement. The Employment Agreement is hereby terminated and of no further force or effect; provided, however, that the Executive will continue as a full-time, at-will employee of the Company and will continue to serve as the Chief Executive Officer of the Company at the discretion of the Board of Directors of the Company. The parties each acknowledge and agree that the termination of the Employment Agreement will not trigger, and shall not be construed to trigger, any rights of the Executive to receive severance or any other payment from the Company.

 

2.        Waiver of Option. The Executive acknowledges and agrees that he has not been granted, and will not be granted, the Option described in Section 5(a). The Executive hereby waives all rights to receive any interest in the Option and fully and forever releases the Company and each of its officers, directors, employees, stockholders, affiliates and assigns from any claim, duty, obligation or cause of action arising out of or relating to the Option.

 

3.      General Provisions.

 

(a)      Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed to be an original but all of which together will constitute one and the same instruments. One or more counterparts of this Agreement may be delivered by facsimile, with the intention that delivery by such means shall have the same effect as delivery of an original counterpart thereof.

 

(b)      Entire Agreement. This Agreement sets forth the entire agreement between the parties hereto and supersedes and cancels all prior agreements or understandings between the parties with respect to termination of the Employment Agreement; provided, however, that the Confidentiality Agreement as defined in Section 11 and any similar agreements, such as a Proprietary Information and Inventions Agreement with a subsidiary of the Company, will survive and continue in full force and effect. The Executive acknowledges and agrees that he has not relied on any representations, promises, or agreements of any kind made to him in connection with this Agreement or termination of the Employment Agreement.

 

  

  

  

 

(c) Governing Law. The validity, interpretation, construction and performance of this Agreement shall be governed by the laws of the Washington without regard to its conflicts of law principles.

 

IN WITNESS WHEREOF, the parties hereto have executed this Agreement, effective as of the date first written above.

 

Cocrystal Pharma, Inc.

 

By: /s Steven D. Rubin

Steven D. Rubin, Director

Executive

By: /s/ Gary Wilcox

       Dr. Gary Wilcoxex10-6.htm

Exhibit 10.6

 

FIRST AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT

 

This First Amendment to Executive Employment Agreement (this "Amendment") between Cocrystal Pharma, Inc., a Delaware corporation (f/k/a Biozone Pharmaceuticals, Inc.) (including its successors and assigns, the "Company"), and Dr. Sam Lee (the "Executive") is dated as of February 23, 2015. This Amendment amends the Executive Employment Agreement dated as of January 2, 2014 by and between the Company and Executive (the "Employment Agreement"). Capitalized terms used but not defined herein shall have the meanings given to such terms in the Employment Agreement. All references to Sections herein shall be references to such Sections in the Employment Agreement unless otherwise noted.

 

RECITALS

 

WHEREAS, the parties hereto desire to amend certain terms of the Employment Agreement to reflect certain agreed-upon modifications to the Executive's compensation and benefits, upon the terms set forth herein;

 

NOW THEREFORE, in consideration of the foregoing, of the mutual promises contained herein and of other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:

 

1. Section 5. Sections 5(a) and 5(b) are hereby deleted in their entirety. The Executive acknowledges and agrees that (i) he has not been granted the Option described in Section 5(a) and (ii) the effect of the deletion of Sections 5(a) and 5(b) is that the Executive will not have the right to receive the Option. The Executive hereby waives all rights to receive any interest in the Option and fully and forever releases the Company and each of its officers, directors, employees, stockholders, affiliates and assigns from any claim, duty, obligation or cause of action arising out of or relating to the Option.

 

2. Section 7(d). Section 7(d) is hereby amended in its entirety to read as follows: "Upon written notice by the Company to the Executive of an involuntary termination without Cause and other than due to death or Disability."

 

3. Section 8(d). Section 8(d) is hereby amended by:

 

(a)      changing "twelve (12) months" in the second line of Section 8(d)(1) to "six (6) months";

 

(b)      inserting an "and" at the end of the Section 8(d)(3);

 

(c)      deleting "; and" at the end of Section 8(d)(4) and replacing it with a period; and

 

(d)      deleting Section 8(d)(5) in its entirety.

4. Section 7(e). Section 7(e)(5) shall be amended in its entirety to read as follows: "(5) a requirement that the Executive relocate to a principal place of employment more than forty (40) miles from his then current place of employment with the Company; or".

5. General Provisions.

(a)      Successors and Assigns. This Amendment shall be binding upon and inure to the benefit of the Company and its successors, assigns and legal representatives.

 

(b)      Counterparts. This Amendment may be executed in counterparts, each of which shall be deemed to be an original but all of which together will constitute one and the same instruments. One or more counterparts of this Amendment may be delivered by facsimile, with the intention that delivery by such means shall have the same effect as delivery of an original counterpart thereof.

 

  

  

  

(c)      Entire Agreement. This Amendment, together with the Employment Agreement, sets forth the entire agreement of the parties hereto in respect of the subject matter contained herein. No agreements or representations, oral or otherwise, express or implied, with respect to the subject matter hereof have been made by either party which are not expressly set forth in this Amendment. Except as amended by this Amendment, the Employment Agreement shall remain in full force and effect in accordance with its terms and conditions, and is hereby ratified and confirmed.

(d)      Governing Law. The validity, interpretation, construction and performance of this Amendment shall be governed by the laws of the Washington without regard to its conflicts of law principles.

IN WITNESS WHEREOF, the parties hereto have executed this Amendment, effective as of the date first written above.

Cocrystal Pharma, Inc.

By: /s/ Gary Wilcox

Dr. Gary Wilcox, Chief Executive Officer

Executive

By: /s/ Dr. Sam Lee

  Dr. Sam LeeExhibit 4.8

 

CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN
OMITTED AND ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST. COPIES OF THIS EXHIBIT CONTAINING THE OMITTED INFORMATION HAVE BEEN
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. THE OMITTED PORTIONS OF THIS DOCUMENT ARE MARKED WITH A [***].

 

EQUIPMENT PURCHASE AGREEMENT

 

This EQUIPMENT PURCHASE AGREEMENT (the “Agreement”),
effective as of September 24th , 2014 (the “Effective Date”), is made by and between ITAMAR-MEDICAL
LTD., a company organized under the laws of the State of Israel, having a place of business at 9 Halamish St., Industrial Park,
Caesarea 38900, Israel, (“Itamar” or the “Company”), and GALMED RESEARCH AND DEVELOPMENT
LTD., a company organized under the laws of the State of Israel with offices at 8, Shaul Hamelech Blvd., Tel Aviv 64733, Tel-Aviv,
Israel (“Galmed”).

 

WITNESSETH

 

WHEREAS, the Company wishes to enable
Galmed to purchase certain Products as defined herein, all under the terms and conditions set forth herein.

 

NOW, THEREFORE, for and in consideration
of the covenants and conditions hereinafter set forth, it is agreed by and between the parties as follows:

 

1.          Sale
of Products. Subject to the provisions of this Agreement, the Company, will sell Products (“Products”) and
subject to receiving certain study data as agreed between the parties in advance, will provide certain support to Galmed with regard
to the Products, as set forth in Exhibit A hereto.

 

2.          Sale
Process; Delivery; Upon signing the agreement Itamar will ship the Products into a location provided by Galmed in advance,
in the quantity, as specified in Exhibit A. Any time Galmed wishes to purchase additional Products, it shall issue a written
Purchase Order (“PO”) to the Company detailing the type and number of Products required and the location to which these
products are requested to be shipped. Such notification shall be delivered to the Company at least 30 days prior to the desired
date of shipment. The cost of such additionally ordered Products is specified in Exhibit B.

 

3.          Consideration;
Payment Terms; The consideration for the sale of Products and the payment terms are set forth in Exhibit A hereto.
All prices set forth in Exhibit A and Exhibit B are based
on delivery ex works, Itamar's Caesarea, Israel facilities, as that term is defined in Incoterms 2010, ICC Rules for the Use of
Domestic and International Trade Terms, ICC Publication No. 715EF (the “Delivery Point”). Galmed assumes
all risks of loss or damage to the Products from any cause, as well as any fees or taxes incurred after delivery.

 

4.      Terms
of Use.

 

4.1         Galmed
will make sure that the Products are maintained in good operating condition, and are serviced and repaired when necessary to keep
the Products in good operating condition. All use and maintenance must be done according to the Company's requirements or recommendations
as described in the Product's Operating Manual provided by the Company. All maintenance must also comply with any legal and/or
regulatory requirements. Galmed shall pay all costs related to compliance with the provisions of this Section.

 

    	 

    	 

    

 

4.2           The
Company has a right, upon prior notice coordinated with Galmed to inspect the Products and to ensure compliance with the terms
hereof.

 

4.3           The
Products will not be altered, tampered with or modified without the Company's prior written consent.

 

5.    All
proprietary and sensitive information, disclosed by or on behalf of Galmed to the Company including any of the Company’s
representatives or learned by the Company and/or its representatives in connection with and in the course of performing of this
Agreement, regardless of form, and any proprietary and sensitive information generated or resulting from the use of the Product
(“Galmed's Confidential Information”), shall be treated as confidential both during the term of the Agreement and following
its termination for a period of five (5) years. During such time period, the Company undertakes to maintain Galmed's Confidential
Information in confidence and to use all reasonable efforts to ensure that its representatives maintain Galmed's Confidential Information
in confidence, except as otherwise provided in this Agreement. The foregoing restrictions shall not apply to Galmed's Confidential
Information which is, or becomes part of the public domain through no act or omission of the Company and/or was lawfully obtained
by the Company from another source. The Company shall be liable for any breach of this section by any of its personnel, including
by its representatives. Also, the Company shall not publicize the results of any non-public data derived from Galmed’s “ARAMCHOL005
study” and "ARAMCHOL007 study" without Galmed’s prior consent.

 

6.    Warranty;
Defects; Limitation of Liability. 

 

6.1           EXCEPT AS SET FORTH IN THIS SECTION
6, THE COMPANY MAKES NO WARRANTIES OF ANY KIND HEREUNDER, WHETHER EXPRESS, IMPLIED OR ARISING FROM TRADE USAGE, CONTRACT, TORT
OR OTHERWISE, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.

 

IN NO EVENT SHALL THE COMPANY BE LIABLE FOR
SPECIAL, INDIRECT OR CONSEQUENTIAL DAMAGES OR LOST PROFITS OR REVENUES ARISING OUT OF THIS AGREEMENT OR IN CONNECTION WITH THE
USE OR PERFORMANCE OF, OR RESULTS OBTAINED OR NOT OBTAINED FROM THE USE OF THE PRODUCTS, BY GALMED, HOSPITALS, OR OTHERWISE.

 

6.2           Subject to 4.1, 4.2, 4.3, 11, the Company
hereby warrants to Galmed that: (1) each Product to be delivered hereunder will be free of defects in material and workmanship
under normal use and service for a period of twenty seven months from the date of delivery (the “Warranty Period”).

 

6.3           If,
during the Warranty Period, a Product or any component of the Products becomes defective by reason of material or workmanship,
and provided that Galmed immediately notifies the Company, the Company will as an option immediately repair the defect on site
or supply a replacement which will be shipped within 48 hours and request the return of defective equipment to Company's premises
for repair in accordance with Company's warranty and repair procedures.

 

6.4           The
site coordinator in each site will receive the product in every site and check the Product for defects and whether the Product
arrived in whole and will immediately notify Galmed and the Company if errors occurred and/or defected Products were identified.
The Company's staff trainer shall then also check the Products for defects and whether the Product arrived in satisfactory condition
and shall immediately notify Galmed and the Company if errors occurred and/or defected were identified.  

 

    	2

    	 

    

 

6.5         The
parties shall share the cost of shipping replacements and returning defected products.

 

6.6         This
warranty shall not apply to any Products or component parts, that (a) have been damaged by improper operation, tampering with,
improper maintenance, misuse, accident, or neglect, or were subject to any prohibited activities; (b) have been used in a manner
not in accordance with the instructions supplied by the Company; (c) have had changes or repairs made without written authorization
of the Company to do so; (d) were incorporated into another product without the prior written approval of the Company; or (e) were
stored in conditions and/or for a period of time contrary to the guidelines of the Company which proves to be inadequate or unreasonable.

 

7.          All
rights and title to and/or interests in the results derived from using the Products by Galmed in the “ARAMCHOL005 and ARAMCHOL007
studies” are and shall be owned by and are and will be the exclusive property of Galmed, and shall be deemed the confidential
information of Galmed.

 

8.          Indemnification.
Galmed agrees to indemnify the Company and hold it harmless from and against any and all liability, fines, suits, claims, demands,
actions, costs and expenses of any kind that arise or be claimed against the Company by any person as a result of an act of negligence
or omission to use the Products by Galmed, its employees and service providers, including, but not limited to its obligations under
Section 4 above, except for such damages or losses resulting from the use of the Products conducted in accordance with section
4 above.

 

9.          Default.
If Galmed is in default on any provision of the terms of this Agreement, all of Galmed’s payment obligations to the Company
shall immediately become due and payable, and the Company may, without notice, decline to make further shipments, deliveries or
terminate Galmed’s outstanding POs, without affecting any other right or remedy the Company may have, including, but not
limited to, any right to cancellation charges. For purposes of this Agreement, a “default” shall occur in the event
that Galmed is more than five (5) days delinquent in any payment to the Company, becomes insolvent, is adjudicated bankrupt, petitions
for or consents to any relief under any bankruptcy reorganization statutes, has a receiver appointed or makes an assignment for
the benefit of creditors, or is otherwise unable to meet its financial obligations as they become due. Continued shipment by the
Company following Galmed’s default shall not constitute a waiver nor shall it affect Galmed’s legal obligations hereunder.

 

10.        Term
and Termination of this Agreement.

 

10.1      This
Agreement enters into effect on the Effective Date and shall remain in effect until the earliest of (i) the completion of Galmed's
phase IIb clinical trial entitled ARAMCHOL005 and Galmed's receiving all final Core Lab reports from the Company and the Company
receiving all data agreed between the parties in advance (ii) occurrence of termination by either party in an event of a breach
of a material provision hereof that has not been remedied during a period of 14 days after the delivery of a notice thereof by
the non-breaching party to the party in breach.

 

10.2      In any event of
termination of this Agreement, except for event of a material breach by Galmed, the relevant provision of Section 3, 4, 5, 6, 8,
9, 10 and 12 of this Agreement shall remain in effect with respect to Products at such time.

 

11.         Assignment.
Without the prior written consent of the Company, Galmed shall not (1) assign, transfer, pledge or hypothecate this agreement,
or any part thereof, or any interest therein except to a successor in case of a merger, acquisition or as part of a transaction
transferring all or substantially all the business or assets of Galmed or (2) sublet or lend the Products or permit them to be
used by anyone other than Galmed, Galmed’s employees and any of Galmed’s agents conducting clinical studies.

 

    	3

    	 

    

 

12.   Disclosure. Neither
Party shall disclose, publicize or advertise in any manner the discussions or negotiations contemplated by the Agreement without
the prior written consent of the other Party, except as may be required by law.

 

13.   Governing Law; Disputes.
This Agreement shall be governed by and construed in accordance with the laws of Israel. The competent courts and tribunals situated
in Tel Aviv, Israel shall have sole and exclusive jurisdiction in any dispute or controversy arising out of or relating to this
Agreement.

 

14.   This Agreement is not
intended by the parties to constitute or create a joint venture, pooling arrangement, partnership, agency, employer-employee relationship
or a formal business organization of any kind.

 

15.   Publication. The
Company shall not publicize the data shared with the Company and results of any non-public data derived from Galmed’s ARAMCHOL005
study and ARAMCHOL007 study without prior consent of Galmed.

 

16.   This Agreement, together
with the Exhibit(s), sets forth the entire agreement between the parties on the subject hereof and supersedes any previous agreement,
understanding, memorandum, letter of intent or representation on the subject matter hereof. This Agreement may be amended only
by written agreement signed by the duly empowered representatives of both parties.

 

17.   Insurance.
The Company warrants that it maintains, at its sole cost and expense, an adequate policies of general liability insurance in amounts
of $1 million per occurrence and $2 million in the annual aggregate to insure its obligations
hereunder. 

 

IN WITNESS WHEREOF, each of the parties
has caused this Agreement by a duly authorized representative on the dates entered herein below.

 

	ITAMAR-MEDICAL LTD.	 	GALMED RESEARCH AND DEVELOPMENT LTD.
	 	 	 	 
	By:	/s/ Gilad Glick	 	By: /s/ Allen Baharaff
	 	 	 	 
	Name:	Gilad Glick	 	Name: Allen Baharaff
	 	 	 	 
	Title:	CEO	 	Title: CEO
	 	 	 	 
	Date:	24 November 2014	 	Date: 24 Sept 2014
	 	 	 	 
	By:	/s/ Shaul Sharoni	 	 
	 	 	 	 
	Name:	Shaul Sharoni	 	 
	 	 	 	 
	Title:	CFO	 	 
	 	 	 	 
	Date:	24 November 2014	 	 

 

    	4

    	 

    

 

EXHIBIT A

PRODUCTS AND PRICES

 

		I.	The Company’s
Product:

 

The Product includes:

		1.	EndoPAT kit composed of

		 ̈	EndoPAT device

		 ̈	Two hand supports

		 ̈	High pressure occluding cuff

		 ̈	Manometer

		2.	Preconfigured laptop with the EndoPAT software

		3.	A box of single-use EndoPAT probes includes 6 (Six) pairs
of single use probes in the box – one pair is required per test

		4.	An envelope with the necessary equipment certificates
and list of contents that are necessary for shipment (the "Shipment Documents")

 

In consideration for and subject to providing
EndoPAT test results and study demographics to the Company that shall be used for internal purposes only, Galmed will be granted
the following support at no additional cost:

		1.	A project manager will be assigned to the study at the
Company and will serve as a focal point for the participating sites and Galmed.

		2.	The Company's representative’s participation in and
presenting at investigator’s meetings will involve reimbursement of travel costs only as pre-approved by Galmed.

		3.	A hotline with a toll-free number for technical support
will be provided to each participating study site at any reasonable time.

		4.	An on-site installation and staff training by the Company's
experts for each participating site.

		5.	A core lab for the EndoPAT testing that includes:

		a.	EndoPAT data analysis (test result) and test quality score
(good, fair, inadequate) for each test.

		b.	Fast feedback to sites on the first recordings of the
study, to minimize the learning curve and prevent any sub-optimal performance entering the study.

		c.	The Company shall submit a final Core Lab written report
to Galmed, summarizing its data, findings and the results of deriving from the use of the Products in connection with Galmed's
ARAMCHOL005 study and ARAMCHOL007 study, as well as a detailed interpretation of such data ("Core Lab Report"), within
30 days after data lock up of each study.

 

II. Quantity of Products to be
provided by the Company to Galmed:

		1.	Sixty (60) EndoPAT devices including 60 envelops of Shipment
Documents.

		2.	Sixty (60) Preconfigured laptop with the EndoPAT software

		3.	One hundred thirty two (132) boxes of single use EndoPAT
probes

III. Total Cost to be paid by Galmed:
A total cost of 750,000 USD, not including taxes, for the Products in Item II referenced above, provided that the agreement is
signed and all Products specified in Item II above are shipped to Galmed by September 29th, 2014.

 

    	5

    	 

    

 

		I.	Terms of payment: Payment of the total cost
referenced in Item II, including taxes shall be paid in full no later than December 30th, 2014.

 

    	6

    	 

    

 

EXHIBIT B

 

COST LIST FOR ADDITIONAL PRODUCTS THAT
MAY BE PURCHASED BY GALMED UNDER THE TERMS OF THIS AGREEMENT

 

		1.	Additional EndoPAT device(s), each at [***] USD (a [***]%
discount will be applied if the terms of the first order as specified in EXHIBIT A have been met).

		2.	Preconfigured laptop with the EndoPAT software at [***]
USD (a [***]% discount will be applied if the terms of the first order as specified in EXHIBIT A have been met).

		3.	Box of 6 pairs of single use EndoPAT probes at [***] USD
(a [***]% discount will be applied if the terms of the first order as specified in EXHIBIT A have been met).

 

CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN
OMITTED AND ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST. COPIES OF THIS EXHIBIT CONTAINING THE OMITTED INFORMATION HAVE BEEN
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. THE OMITTED PORTIONS OF THIS DOCUMENT ARE MARKED WITH A [***].

 

    	7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00242-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00242-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00242-of-00352.parquet"}]]